Pfizer's anti-TNF-alpha Nanobody (ATN-103) successfully completes a phase II study
Pfizer has now confirmed that clinical proof-of-concept has been achieved and they are now engaged in a full technical, clinical and commercial evaluation to determine whether and how to take ATN-103 forward.
Dr Edwin Moses, Chairman and CEO commented: "We are delighted to announce the first clinical proof-of-concept for a Nanobody. This has extremely important implications for Ablynx, the whole Nanobody technology platform and our R&D pipeline containing more than 25 programmes. Our progress has been rapid and we are excited to have passed this critical milestone in our development into a potentially leading biopharmaceutical company. We look forward to the completion of Pfizer's internal decision making process."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.